Skip to main content
SpringerLink
Log in

Nusinersen not cost effective for spinal muscular atrophy

  • Clinical study
  • Published:
PharmacoEconomics & Outcomes News

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Notes

  1. 2018 Swedish krona

Reference

  • Zuluaga-Sanchez S, et al. Cost Effectiveness of Nusinersen in the Treatment of Patients with Infantile-Onset and Later-Onset Spinal Muscular Atrophy in Sweden. PharmacoEconomics : 4 Feb 2019. Available from: URL: https://doi.org/10.1007/s40273-019-00769-6

Download references

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Nusinersen not cost effective for spinal muscular atrophy. PharmacoEcon Outcomes News 822, 25 (2019). https://doi.org/10.1007/s40274-019-5677-0

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40274-019-5677-0

Search

Navigation